Shane Cooke - Prothena Plc Independent Director
| PRTA Stock | USD 21.42 1.08 5.31% |
Director
Mr. Shane M. Cooke is Independent Director of Prothena Corporation plc., since December 2012. He is the former President of Alkermes plc, a position he held from 2011 to 2018. Prior to that, he served as Head of Elan Drug Technologies and Executive Vice President of Elan Corporationrationration, plc, where he also served as Chief Financial Officer and as a director . Mr. Cooke has also held a number of senior positions in finance in the banking and aviation industries. He is also a director of Alkermes plc and Endo International plc since 2012.
| Age | 54 |
| Tenure | 12 years |
| Address | 77 Sir John Rogerson?s Quay, Dublin, Ireland, D02 VK60 |
| Phone | 353 1 236 2500 |
| Web | https://www.prothena.com |
Prothena Plc Management Efficiency
The company has return on total asset (ROA) of (0.1642) % which means that it has lost $0.1642 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2485) %, meaning that it created substantial loss on money invested by shareholders. Prothena Plc's management efficiency ratios could be used to measure how well Prothena Plc manages its routine affairs as well as how well it operates its assets and liabilities. As of May 1, 2024, Return On Tangible Assets is expected to decline to -0.21. The current year's Return On Capital Employed is expected to grow to -0.28. At present, Prothena Plc's Other Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 42.3 M, whereas Total Assets are forecasted to decline to about 414.8 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Amy Hanson | LSI Industries | N/A | |
| Leslie Brun | Merck Company | 68 | |
| Mark Serrianne | LSI Industries | 67 | |
| Robert Kidder | Merck Company | 71 | |
| Wilfred OGara | LSI Industries | 60 | |
| Carlos Represas | Merck Company | 72 | |
| John Morgan | LSI Industries | 63 | |
| Christine Seidman | Merck Company | 68 | |
| William Harrison | Merck Company | 70 | |
| Dennis Meyer | LSI Industries | 80 | |
| Rochelle Lazarus | Merck Company | 71 | |
| Robert Beech | LSI Industries | 64 | |
| Peter Wendell | Merck Company | 70 | |
| John Noseworthy | Merck Company | 66 | |
| Paul Rothman | Merck Company | 63 | |
| Thomas Cech | Merck Company | 72 | |
| Patricia Russo | Merck Company | 68 | |
| Gary Kreider | LSI Industries | 78 | |
| Mary Coe | Merck Company | 54 | |
| Kathy Warden | Merck Company | 49 | |
| Thomas Glocer | Merck Company | 61 | |
Management Performance
| Return On Equity | -0.25 | ||||
| Return On Asset | -0.16 |
Prothena plc Leadership Team
Elected by the shareholders, the Prothena Plc's board of directors comprises two types of representatives: Prothena Plc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Prothena. The board's role is to monitor Prothena Plc's management team and ensure that shareholders' interests are well served. Prothena Plc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Prothena Plc's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Hideki MD, Chief Officer | ||
| Christopher Henney, Independent Director | ||
| Paula Cobb, Director | ||
| Sarah Noonberg, Chief Medical Officer | ||
| Tara Nickerson, Chief Business Officer and Secretary | ||
| Jennifer Zibuda, Director Communication | ||
| Lars Ekman, Independent Chairman of the Board | ||
| Brandon Smith, Chief Officer | ||
| Carol Karp, Chief Regulatory Officer | ||
| David Ford, Chief Officer | ||
| Yvonne Tchrakian, Company Sec | ||
| Karin CPA, Chief Controller | ||
| Gene Kinney, Chief Scientific Officer and Head of RandD | ||
| Shane Cooke, Independent Director | ||
| CPA CPA, Chief Controller | ||
| Dale Schenk, CEO and President and Director | ||
| Richard Collier, Independent Director | ||
| David McNinch, Chief Commercial Officer | ||
| Dennis Selkoe, Independent Director | ||
| Arthur Homan, Chief Legal Officer | ||
| Tran Nguyen, CFO | ||
| Martin Koller, Chief Medical Officer | ||
| Anders Harfstrand, Director | ||
| Wagner Zago, Chief Scientific Officer | ||
| Karin Walker, Chief Accounting Officer and Controller | ||
| Michael Malecek, Chief Secretary | ||
| Mark CFA, Vice Relations | ||
| Tran MBA, CFO Officer |
Prothena Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Prothena Plc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.25 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (1.61) % | ||||
| Operating Margin | (248.47) % | ||||
| Current Valuation | 485.68 M | ||||
| Shares Outstanding | 53.72 M | ||||
| Shares Owned By Insiders | 12.43 % | ||||
| Shares Owned By Institutions | 87.57 % | ||||
| Number Of Shares Shorted | 6.63 M | ||||
| Price To Earning | 37.12 X |
Prothena Plc Investors Sentiment
The influence of Prothena Plc's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Prothena. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Prothena Plc's public news can be used to forecast risks associated with an investment in Prothena. The trend in average sentiment can be used to explain how an investor holding Prothena can time the market purely based on public headlines and social activities around Prothena plc. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Prothena Plc's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Prothena Plc's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Prothena Plc's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Prothena Plc.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Prothena Plc in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Prothena Plc's short interest history, or implied volatility extrapolated from Prothena Plc options trading.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Prothena plc using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Prothena plc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Prothena Stock refer to our How to Trade Prothena Stock guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Prothena Stock analysis
When running Prothena Plc's price analysis, check to measure Prothena Plc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Prothena Plc is operating at the current time. Most of Prothena Plc's value examination focuses on studying past and present price action to predict the probability of Prothena Plc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Prothena Plc's price. Additionally, you may evaluate how the addition of Prothena Plc to your portfolios can decrease your overall portfolio volatility.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |
Is Prothena Plc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Prothena Plc. If investors know Prothena will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Prothena Plc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.65) | Revenue Per Share 1.717 | Quarterly Revenue Growth (0.99) | Return On Assets (0.16) | Return On Equity (0.25) |
The market value of Prothena plc is measured differently than its book value, which is the value of Prothena that is recorded on the company's balance sheet. Investors also form their own opinion of Prothena Plc's value that differs from its market value or its book value, called intrinsic value, which is Prothena Plc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Prothena Plc's market value can be influenced by many factors that don't directly affect Prothena Plc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Prothena Plc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Prothena Plc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Prothena Plc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.